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ABSTRACT. It is now thirty years since the first report of a potent zinc-dependent 
histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have 
received regulatory approval for cancer chemotherapy, while many others are in clinical 
development for oncology as well as other therapeutic indications. This perspective 
reviews the biological and medicinal chemistry advances over the last three decades 
with an emphasis on the design of selective inhibitors that discriminate between the 
eleven human HDAC isoforms.
Introduction
The human genome contains a modest number of 20,000-25,000 genes coded by only 
5% of its DNA sequence. However, it is not the case that ‘one gene = one protein’, as 
processes such as mRNA editing lead to a transcriptome that is several-fold higher than 
the number of genes. A further expansion occurs after protein synthesis through the 
post-translational modification (PTM) of amino acid side chains. The majority of PTMs 
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are dynamic in nature, enabling a single protein to exist in multiple functional states and 
move from one state to another in a reversible manner. The -amino side chain of 
lysine, in particular, is the conduit for a plethora of PTMs (Figure 1) via alkylation or 
acylation reactions.1,2 Alkylation increases the size of the lysine side chain while 
preserving its positively charged nature at physiological pH, whereas acylation results in 
neutral or even negatively charged side chains ranging from the addition of a single 
carbon in formylation to the conjugation of proteins such as ubiquitin. Two of these 
processes, acetylation and methylation, occur in the lysine-rich N-terminal tails of 
histone proteins where they play a central role in the epigenetic regulation of chromatin 
structure and the recruitment of its binding partners to modulate gene transcription. 
Consequently, the enzymes involved in lysine acetylation and methylation and their 
removal have become important targets for small molecule drug discovery.3 At the 
present time, five inhibitors of lysine deacetylation, and one of lysine methylation, have 
received regulatory approval as anticancer agents. This year marks the 30th 
anniversary of the disclosure of the natural product trichostatin A as the first potent 
inhibitor of histone deacetylation. In this perspective, we summarize the progress since 
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then regarding the biology of lysine deacetylase enzymes, the compounds currently in 
clinical development against this target and the discovery of isoform selective inhibitors. 
Previous reviews in this journal provide a snapshot of the state of the art at earlier time 
points.4,5
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Figure 1. Examples of lysine post-translational modification in proteins.
Lysine acetylation was first observed in the early 1960s in histones due to the 
abundance of the PTM in these proteins. Soon thereafter, enzymes that catalyze the 
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forward acetylation reaction and the reverse deacetylation reaction were discovered and 
logically named histone acetyltransferases (HATs) and histone deacetylases (HDACs) 
respectively.  Unfortunately, this historical nomenclature is well entrenched despite its 
inaccuracy, as we now know that lysine acetylation is not restricted to histones but a 
widespread PTM in thousands of human proteins present in diverse cellular 
compartments.6 The PTM is produced via the transfer of an acetyl group from acetyl 
CoA to a lysine residue, either by a reaction catalyzed by HATs or through an enzyme-
free process. Acetylation can dramatically alter the biological properties of a protein 
(Table 1) as well as being the chemical signal for recognition by bromodomains, a 
protein-protein interaction subunit found in transcriptional activators.7 Meanwhile, a 
variety of other acyl CoA species undergo a similar reaction with lysine residues in vivo 
to create distinct PTMs.8 These include short and medium-chain saturated carboxylic 
acids such as formic, propionic, butyric and myristic; short-chain dicarboxylic acids such 
as malonic, succinic and glutaric; and carboxylic acids with additional functionality such 
as 2-hydroxyisobutyric, crotonic, phosphoglyceric, lipoic and biotin. Although the precise 
physiological roles of many of these recently discovered acyllysine PTMs are yet to be 
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deciphered, the inadequacy of the nomenclature’s emphasis on histone proteins and 
acetylation is apparent. 
Acetylation consequence Examples
Reduced nucleic acid binding Histone-DNA, E2F-DNA
Increased protein binding Histone-PCAF, Histone-BRD4 
Reduced protein binding Hsp90-GR, Ku70-p23
Increased stability p53, -tubulin
Decreased stability DNMT1, HIF1
Reduced enzymatic activity Aurora B kinase, RNase II
Altered cellular localization STAT3, c-Abl
Altered aggregation Tau, GRP78 
Table 1. Examples of the consequences of lysine acetylation in human proteins.
The eleven human HDACs
The reversal of lysine acetylation is accomplished by enzymatic cleavage catalyzed by 
the HDACs. In humans, there are 18 HDACs that fall into two families based on their 
catalytic mechanism.9 Eleven of the HDACs are zinc-dependent metalloenzymes 
named HDAC1-11 that hydrolyze the amide bond using water as a nucleophile. The 
remaining seven sirtuins 1-7 employ NAD+ as a cofactor and transfer the acyl group to 
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the C2 position of the ribose sugar.10 Although both enzyme families perform the same 
chemical reaction of acyllysine cleavage, the term HDAC usually refers to the zinc-
dependent enzymes that are the focus of this perspective.11 
X-ray crystal structures are available for the majority of HDAC isoforms with the free 
protein, protein-inhibitor complexes as well as substrates bound to mutated proteins that 
do not turnover. These extensive studies have provided a detailed understanding of the 
catalytic mechanism, as exemplified in the model for HDAC8.12 The acetyllysine 
substrate sits in a narrow channel lined with hydrophobic residues, with a tyrosine 
residue flipping in conformation to enable hydrogen bonding with the carbonyl oxygen 
(Figure 2A).  The hydrophobic nature of the channel, and the conformational change by 
the tyrosine residue, serve to provide enzyme specificity for the acyllysine side chain. A 
zinc cation, coordinated to aspartate and histidine residues, sits at the end of the 
substrate channel, bound to a water molecule activated by a charge relay mechanism 
with two adjacent histidine residues. Nucleophilic attack of the carbonyl by the water 
produces a tetrahedral oxyanion intermediate (Figure 2B), which collapses to give rise 
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to the free lysine and acetate products (Figure 2C). In some HDAC isoforms, there is an 
additional hydrophobic internal cavity lateral to the active site also known as the ‘foot 
pocket’. This cavity accommodates acyl side chains longer than acetyl in the case of 


























Figure 2. A simplified illustration of the catalytic mechanism of deacetylation by HDACs: 
A. Enzyme-substrate complex, with binding interactions between the acetyllysine 
bearing protein substrate and a tyrosine residue and the zinc cation in the HDAC active 
site. B. The tetrahedral oxyanion enzyme intermediate arising from nucleophilic attack 
by water. C. Enzyme-product complex, with the lysine residue and acetate prior to 
release from the active site. 
It is worth highlighting a few key points regarding the HDAC enzymes:
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1. Substrate binding is predominantly through the acetyllysine side chain entering the 
hydrophobic channel rather than recognition of the protein backbone. In some cases, 
bonding interactions are observed between HDACs and the amino acid residues that 
are +1 or -1 with respect to the scissile acetylysine. However, extended contacts such 
as occur in peptide backbone recognizing proteases are rare in HDACs which are 
relatively nonspecific in their substrate sequence preferences. The compact nature of 
substrate binding is an advantage for medicinal chemistry, as small molecule inhibitors 
need only simulate acetyllysine rather than a longer peptide sequence.
2. Coordination between acetyllysine and the active site zinc cation is critical for 
substrate binding and catalysis. Indeed, all high affinity HDAC inhibitors barring covalent 
modifiers achieve their potency by zinc coordination, acting as either monodentate or 
bidentate ligands to mimic the tetrahedral oxyanion intermediate.
3. In broad terms, the features of the HDAC8 catalytic mechanism hold true for other 
isoforms. Nevertheless, there are significant variations in the geometry of the active site, 
the nature of the catalytic residues, the substrate channel, presence or absence of the 
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internal cavity and positioning of adjacent protein loops. Selective inhibitors that 
discriminate between HDAC isoforms will need to take advantage of such differences.
The human histone deacetylases are further subdivided into four classes according to 
their sequence homology and cellular localization: Class I = HDAC1, HDAC2, HDAC3 
and HDAC8; Class IIa = HDAC4, HDAC5, HDAC7 and HDAC9; Class IIb = HDAC6 and 
HDAC10; Class III = sirtuins 1-7; Class IV = HDAC11. However, this classification is 
somewhat arbitrary and masks the similarities or differences between isoforms in terms 
of structure and function. In cell-free biochemical assays, HDAC1, HDAC2, HDAC3 and 
HDAC6 have high enzymatic activity against simple acetyllysine containing peptides 
and will be discussed first, followed by the other isoforms that are more mysterious in 
their substrate preferences.
HDAC1, HDAC2
These isoforms are core HDACs that are co-expressed and are ubiquitous within and 
between species.13 Although they efficiently hydrolyze acetyllysine peptide substrates 
on their own in vitro, they predominantly exist in the nucleus as homo- and heterodimer 
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constituents of the NuRD, Sin3A, CoREST, MiDAC and MIER transcriptional repressor 
complexes. While there is >80% homology between HDAC1 and HDAC2, they perform 
independent roles in development and embryonic knockout of either isoform is lethal. 
On the other hand, in conditional knockouts, there is a level of redundancy with 
knockout of both isoforms usually needed for a phenotypic effect. HDAC1 and HDAC2 
are truly HDACs in the sense that they play a major role in histone deacetylation. In 
addition, they deacetylate many other nuclear proteins involved in transcriptional 
regulation including p53, E2F, ATM kinase and CAF1. There is crosstalk with other 
epigenetic processes such as methylation, as both DNMT1 and LSD1 are among their 
substrates.
HDAC3
HDAC3 shares ~50% sequence homology with HDAC1 and HDAC2. The divergence is 
mainly in the C-terminal region, with HDAC3 containing a domain for binding to the 
nuclear NCoR/SMRT complexes.14 In fact, HDAC3 is unstable without the presence of 
either NCoR or SMRT, and their association is also necessary for the activation of 
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catalysis. Interestingly, the X-ray crystal structure of HDAC3 with the deacetylase-
activating domain of SMRT contained a molecule of inositol tetraphosphate at the 
interface, bringing the two proteins together. Like HDAC1/HDAC2, HDAC3 is 
ubiquitously expressed and involved in the deacetylation of histones, while other 
nuclear protein substrates include STAT3 and FOXP3. In addition to distinct roles in 
embryonic development, HDAC3 is implicated in a number of physiological processes 
including circadian rhythms, energy metabolism, neuronal function and bone 
remodeling.
HDAC6
If HDAC1-3 are the nuclear workhorses of lysine deacetylation, then HDAC6 is the 
cytoplasmic equivalent.15 HDAC6 is the largest in size among the HDACs, with a C-
terminal ubiquitin-binding zinc finger domain. A nuclear localization sequence (NLS) is 
opposed by a nuclear export sequence (NES) and Ser-Glu-containing tetrapeptide 
(SE14) repeats that result in the protein mainly being in the cytoplasm. Through the 
deacetylation of -tubulin and cortactin aided by an N-terminal microtubule-binding 
Page 13 of 111
ACS Paragon Plus Environment






























































domain, HDAC6 directly impacts upon the cytoskeleton and cell mobility. Moreover, 
HDAC6 is involved in the repair of protein misfolding, as deacetylation of Hsp90 
restores its chaperone activity while HDAC6’s ubiquitin-binding domain fosters binding 
to misfolded proteins and their targeting for destruction by aggresomes. Additional 
cytoplasmic substrates include Ku70, whose deacetylation leads to a loss in binding to 
BAX and thereby inhibition of apoptosis, and Tau, in which deacetylation alters the 
propensity for aggregation. Further to these cytoplasmic roles, HDAC6 can also localize 
in the nucleus where it functions as a transcriptional repressor similar to HDAC1-3.
Uniquely among the HDACs, HDAC6 contains two catalytic domains CD1 and CD2. 
While CD2 is a robust lysine deacetylase in vitro, CD1 was considered inactive for a 
long time. However, recent studies reveal that CD1 is a competent deacetylase with the 
right substrates, expressing a preference for C-terminal acetyllysine sequences aided 
by the presence of a lysine residue in CD1 that forms electrostatic interactions with the 
carboxylate.16,17 Another unusual feature of HDAC6, unlike other isoforms, is that 
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knockout mice are viable and healthy, and do not express an obviously defective 
phenotype.
HDAC8
HDAC8 is the only isoform for which the gene lies in the X chromosome. Although it is 
grouped as a Class I nuclear HDAC, it is fundamentally distinct from the HDAC1-3 
isoforms in this Class.18 Unlike the others, HDAC8 is smaller in size and acts 
independently, as it is bereft of C-terminal protein-protein interaction domains that 
promote incorporation into multiprotein complexes. In vitro, HDAC8 has a lower kcat/Km 
value for the hydrolysis of acetyllysine containing peptides compared to HDAC1-3 or 
HDAC6. Nevertheless, the catalytic activity is significantly higher against tetrameric 
histone H3/H4 proteins suggesting that histones are, to some extent, in vivo substrates 
for HDAC8.19 Additional nuclear substrates have been identified such as SMC3, p53, 
ERR and ARID1a. Recently, Lin demonstrated that HDAC8 hydrolyzes acyllysine 
peptides with acyl chains of 2-16 carbons, and kcat/Km for the longer acyl chains of 
octanoyl-, dodecanoyl-, and myristoyllysine was higher than for acetyllysine.20 These 
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longer chain acyl groups are likely to be accommodated by extending beyond the active 
site zinc cation to occupy the hydrophobic internal cavity lateral to the substrate 
channel. It may be that fatty acid deacylation is a more important physiological function 
of HDAC8 than deacetylation, which would explain the relatively small number of known 
validated HDAC8 substrates. Physiologically, the incorporation of these longer acyl 
chains into lysine PTMs could act as a sensor of energy metabolism by reporting on the 
relative abundance of different acyl CoA species. Alternatively, some fatty acid acylation 
may occur adventitiously in which case HDAC8 and HDAC11 (see below) could be 
operating as proofreading repair enzymes to remove these PTMs.
HDAC11
HDAC11 was first reported only in 2002 and is the smallest of the HDAC isoforms, with 
its catalytic domain accounting for >80% of the protein sequence. Primarily localized in 
the nucleus, it functions as a transcriptional regulator with an important role in 
immunomodulation.21  As an enzyme, HDAC11 has weak activity against acetyllysine 
substrates. Instead, like HDAC8, it efficiently hydrolyzes acyllysine residues with longer 
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chain lengths such as the C12 dodecanoyllysine and the C14 myristoyllysine.22,23 
Although an X-ray structure of HDAC11 is unavailable, homology modeling suggests 
long chain acyl groups are accommodated within an internal cavity in the same manner 
as HDAC8. Interestingly, HDAC11 is susceptible to product inhibition by free fatty acids 
such as myristic, palmitic, and stearic acids while palmitoyl-coenzyme A and myristoyl-
coenzyme A serve to enhance the fatty acid deacylase activity.  
HDAC4, HDAC5, HDAC7 and HDAC9
These so-called Class IIa isoforms, unlike other HDACs, are expressed in a tissue 
specific manner. They are relatively large in size, with an N-terminal domain that binds 
to the MEF2 family of transcriptional repressors.24 Both an NLS and NES are present, 
enabling the Class IIa isoforms to move between the nucleus and cytoplasm. The 
shuttling is regulated by the reversible phosphorylation of multiple serine residues, with 
the unphosphorylated form being nuclear and acting to influence transcriptional 
regulation. The C-terminal region contains the active site in which the key tyrosine 
residue (Figure 2) is replaced by a histidine, resulting in weak catalytic activity. By using 
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more electrophilic trifluoroacetyllysine containing peptides, it is possible to carry out in 
vitro assays and profile HDAC inhibitors against these isoforms. Whether they are truly 
enzymes in vivo or serve to recognize and bind acetyllysine containing proteins is 
unclear. The evidence suggests they act as a scaffolding protein, bringing together the 
acyllysine substrate and HDAC3 containing multiprotein complexes, with the actual 
hydrolysis carried out by HDAC3. On the other hand, it is worth noting that the 
archetypal zinc amidohydrolase thermolysin contains a histidine residue in a similar 
location within the active site that participates in catalysis.25 Thus, it is conceivable that 
the Class IIa isoforms are catalytically competent, and their true substrates have yet to 
be identified. Alternatively, these HDACs may perform dual functions of recognition of 
an acetyllysine signal followed by slow catalysis as a means of eventual signal 
termination, in a similar fashion to the binding of GTP to GTPases which then destroy 
the nucleotide.
HDAC10
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HDAC10 is found in both the nucleus and cytoplasm, and involved in processes such as 
autophagy, immunoregulation and DNA repair.26 While it appears to function as a 
transcriptional repressor, this activity was puzzlingly independent of lysine 
deacetylation. Recent studies from Christianson have clarified this anomaly and 
convincingly demonstrated that HDAC10 is an acetylpolyamine hydrolase evolutionarily 
related to the prokaryotic homologue.27,28 In HDAC10, a unique 310 helix defined by the 
P(E,A)CE motif  serves to narrow the hydrophobic substrate channel, leading to 
selectivity for acetylpolyamines over more bulky peptides or proteins containing 
acetyllysine residues. While the HDAC10 active site contains the conserved tyrosine 
and histidine residues and the zinc activated water typical in HDAC catalysis (Figure 2), 
an additional negatively charged glutamate residue unique to this isoform acts as a 
gatekeeper to favor the binding of cationic acetylpolyamine residues. In fact, the 
substitution of this glutamate residue by leucine was sufficient to restore acetyllysine 
hydrolytic activity in the mutant enzyme.
Overview
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Our understanding of HDACs is continually evolving with new insights regarding their 
substrates. Until recently, it seemed the family could be unified under the nomenclature 
of protein lysine deacylases or KDACs that would encompass both deacetylation as well 
as the hydrolysis of other amides. However, the discovery that HDAC10 is a small 
molecule polyamine deacetylase means that even the KDAC terminology is no longer 
accurate. Meanwhile, whether HDAC4, HDAC5, HDAC7 or HDAC9 are truly enzymes is 
debatable. The traditional subdivision of human HDACs according to Class I-IV does 
not take these recent developments into account, and we prefer to group them 
according to their in vitro substrate tolerance (Figure 3, Table 2).
While this perspective is focused on the human HDACs, homologues in other species 
offer additional opportunities for drug discovery. The selective targeting of fungal 
HDACs as a means to create novel antifungal agents is one example.29 The 
combination of fluconazole and MethylGene’s MGCD209, an inhibitor of the fungal 
Hos2 HDAC,30 reached Phase 2 clinical trials for the treatment of severe vulvovaginal 
candidiasis, but unfortunately did not show improved efficacy over fluconazole alone. 
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Another major area of research is the HDACs present in parasites responsible for 
neglected tropical disease. The approved HDAC inhibitors and clinical candidates as 
well as novel compounds intended to selectively inhibit the parasite enzymes have 
shown promising results in in vivo models, as summarized in a recent review.31
In vitro Acetyl-Lys peptide hydrolases
Isoform Major
localization
Key features Substrate examples
HDAC1, HDAC2 Nucleus Exist in vivo as 
NuRD, Sin3A, 
CoREST, MiDAC 

















In vitro longer chain Acyl-Lys peptide hydrolases
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for C8, C12, C14 
acyllysine
acyllysine residues




In vitro Ac-polyamine hydrolase
















Table 2. The eleven human HDAC isoforms summarized according to substrate 
preference, localization, and key features.
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Figure 3. A ‘solar system’ of human HDACs: at the core are HDAC1, HDAC2 and 
HDAC3 which exist in multiprotein complexes in the nucleus. These isoforms 
deacetylate histones and transcriptional regulators, and homologues are ubiquitous 
across life forms. Next is HDAC6, responsible for the deacetylation of cytoplasmic 
proteins, followed by an ‘asteroid belt’ of the pseudoenzymes HDAC4, HDAC5, HDAC7 
and HDAC9 with poor catalytic activity. The ‘outer planets’ HDAC8 and HDAC11 
preferentially hydrolyze non-acetyl acyllysine substrates while the distant HDAC10 is a 
polyamine deacetylase.
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The in vitro profiling of HDAC inhibitors in cell-free enzymatic assays invariably involves 
the monitoring of product formation using acetyllysine derivatives or peptides based on 
the N-terminal histone tail sequence that contain an acetyllysine residue.32 Assay kits 
often employ peptides with an AcLys-AMC (aminomethylcoumarin) residue at the C-
terminus which undergoes acetyllysine hydrolysis by HDACs (Figure 4). The resulting 
C-terminal lysine is recognized by the exopeptidase trypsin, which cleaves the 
backbone amide to release free aminomethylcoumarin that fluoresces at a longer 
wavelength than the substrate. Although less amenable to high-throughput screening, 
direct detection of product formation by chromatographic separation or mass 
spectrometry without the need for trypsin cleavage are among the alternative formats.33 
In the past, crude cell extracts were used as the source of HDACs, and these mainly 
contained the nuclear isoforms in an unknown ratio. Nowadays, using recombinant 
HDAC proteins, the detailed profiling of compounds to determine their subtype 
selectivity against all eleven isoforms can be accomplished.
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Figure 4. A fluorescence-based assay for measuring HDAC activity based upon product 
cleavage by trypsin to release aminomethylcoumarin.
Due to differences in protein stability and substrate preference, running HDAC assays 
against individual isoforms is actually complicated in practice. With regards to the 
protein, there are options involving full-length enzyme or catalytic domain only, or the 
addition of binding partners to more closely approximate the cellular environment. 
Purity, with the possibility of residual contamination by other isoforms, and batch to 
batch variation are further issues. Simple acetyllysine containing substrates undergo 
efficient hydrolysis by recombinant HDAC1, HDAC2 and HDAC6 in the fluorescent 
assay, as well as HDAC3 when co-expressed with NCoR.34,35 Although such assays are 
operationally convenient, it should be kept in mind that the true substrates are proteins 
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(or multimeric complexes thereof) rather than acetyllysine derivatives or peptides. 
Beyond these isoforms, further tinkering is needed for the other HDACs which have 
lower catalytic activity for acetyllysine hydrolysis. By switching to more labile (but 
artificial) trifluoroacetyllysyl substrates in lieu of acetyllysine derivatives, or using 
mutated enzymes with higher turnover, the inhibition can be quantitatively measured. 
However, these assays may not accurately reflect the in vivo functions of the enzyme. 
For example, HDAC11 preferentially acts upon non-acetyl lysine PTMs and a recent 
assay employing a longer acyllysine substrate showed significant differences compared 
to the traditional trifluoroacetyllysine-based method.36 Similarly, the current HDAC10 kits 
are based on peptides rather than more meaningful acetylpolyamine substrates. As a 
result of all these complexities, care should be exercised in the interpretation of 
literature HDAC IC50 or Ki values taken at different times or from different laboratories, 
and the experimental procedures consulted for the exact assay method employed and 
the data obtained for reference standards.
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In cell-based studies, HDAC inhibitors are usually profiled by their growth inhibition of 
human cancer cell lines, with readouts in other cell types used for non-cancer 
therapeutic indications. Evidence of HDAC target engagement is commonly 
demonstrated by western blotting of the substrate proteins such as histones for nuclear 
HDACs, p53 for HDAC1 and tubulin for HDAC6, to show a dose-dependent elevation of 
acetylation levels. Cellular thermal shift assays (CETSA) are a version that allow for the 
quantification of ligand binding in intact cells.37 The NanoBRET technology based on 
competitive binding between inhibitor and a fluorescent tracer is an alternative approach 
that enables the measurement of target engagement and drug reisdence time in cells.38 
In addition, downstream effects as a result of HDAC inhibition can be measured, 
ranging from phenotypic changes such as cell differentiation to altered protein 
expression levels such as induction of the p21 (CIP1/WAF1) cyclin-dependent kinase 
inhibitor.
Natural product HDAC inhibitors
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To inhibit a HDAC, the logical starting point is to mimic the tetrahedral oxyanion enzyme 
intermediate (Figure 2B) and design a molecule that coordinates to the active site zinc 
cation with a slender hydrophobic linker to fit the substrate binding channel. In addition, 
it is helpful to anchor the molecule at the other end with a cap that can potentially 
engage in additional binding interactions with the rim of the enzyme. In fact, this simple 
model for a HDAC pharmacophore composed of three elements - zinc binding group, 
linker and cap - is sufficiently powerful to account for the vast majority of HDAC 
inhibitors and is widely used since it was proposed by Jung in 1997.39
As the medicinal chemist par excellence, nature has successfully used the three-point 
model for the design of nanomolar HDAC inhibitors with a variety of zinc binding groups, 
linkers and caps. As mentioned in the introduction, the Streptomyces metabolite 
trichostatin A (1, Figure 5) was the first potent HDAC inhibitor to be identified, by 
Yoshida thirty years ago.40 Trichostatin A perfectly illustrates the HDAC 
pharmacophore: the hydroxamic acid functions as a bidentate zinc chelator, as later 
confirmed through X-ray crystallography of trichostatin A-HDAC complexes, while the 
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diene is a rigid linker that sits in the substrate channel and terminates with a substituted 
phenyl ring as the cap. The cap’s tertiary amine substituent, protruding out of the 
enzyme surface, presumably aids in drug solvation by the aqueous environment. 
Psammaplin A (2) isolated from a marine sponge is a symmetrical prodrug, undergoing 
disulfide reduction to the active molecule which conforms to the three-point 
pharmacophore with the thiol as a monodentate zinc binding group.41 Since thiols have 
poor bioavailability, the disulfide protection ensures higher stability and cell permeability 
prior to metabolic activation. A masked thiol prodrug features once again in the 
depsipeptide family of HDAC inhibitors, either as a reducible disulfide in the bacterial 
natural products romidepsin (FK228, 3) and spiruchostatin A (4) or as a hydrolytically 
labile thioester in largazole (5) of cyanobacterial origin.42 Upon metabolism, the free 
thiol common to all three natural products becomes the zinc binding group, as observed 
in the X-ray structure of largazole with HDAC8.
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Figure 5. Examples of potent natural product HDAC inhibitors, with zinc binding atoms 
indicated in red.
While trichostatin A with its simple aromatic cap is a nonselective HDAC inhibitor, both 
romidepsin and largazole contain larger macrocyclic caps that contribute to their 
enzyme affinity as well as enable isoform discrimination.43 The importance of 
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augmenting zinc and substrate channel binding with additional interactions is illustrated 
by the marine sponge natural product azumamide E (6). Synthetic carboxylic acids have 
fared poorly as HDAC inhibitors despite their successful use as zinc binding groups 
against other metalloenzymes. Although the short chain butyric, phenylbutyric and 
valproic acid have been explored as HDAC inhibitors in the clinic, their sole redeeming 
factor is the existence of prior human safety and pharmacokinetic data. The actual 
inhibition of HDACs by these carboxylic acids is weak, verging upon the high 
micromolar level, and they will not be discussed further. Azumamide E, on the other 
hand, achieves submicromolar potency with selectivity for HDAC1 over HDAC6 and the 
macrocyclic scaffold presumably makes a significant contribution to these aspects. 
Interestingly, a synthetic analogue with the carboxylic acid replaced by a bidentate 
hydroxamic acid is even more active as a HDAC inhibitor.44 Trapoxin A (7), one of a 
family of fungal cyclic tetrapeptide HDAC inhibitors, is another interesting example as 
ketones are normally inefficient ligands for zinc. The X-ray structure of 7 with HDAC8 
indicates the ketone is a substrate mimic, reacting with the active site water to form a 
tetrahedral gem-diolate which then functions as a bidentate zinc binding group.45
Page 31 of 111
ACS Paragon Plus Environment






























































Although medicinal chemists work on many epigenetic targets for drug discovery, 
HDACs are apparently the only one that nature has taken seriously and the only one 
against which highly active secondary metabolites have been discovered. This 
emphasis probably reflects the producing microbial or marine organism’s need for 
chemical defense against competing species or predators. In this regard, the rapid 
toxicity arising from HDAC inhibition is evolutionarily more helpful compared to the 
slower consequences of the disruption of DNA or histone methylation. A further 
question is which HDAC should be inhibited, with the core HDAC1/HDAC2 isoforms 
being prime candidates due to their direct impact upon gene transcription and the 
existence of homologues in virtually all species. Indeed, it is unlikely to be a coincidence 
that all the natural products in Figure 5 strongly inhibit HDAC1/HDAC2 with nanomolar 
IC50 values, and except for the nonselective trichostatin A, are less active against the 
cytoplasmic HDAC6. Turner has suggested that evolutionary exposure to natural 
product and environmental HDAC inhibitors may have forced organisms to develop 
resistance mechanisms, and these same pathways are now subverted by tumor cells to 
their advantage upon chemotherapy with such agents.46 
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Clinical candidate and approved HDAC inhibitors
In a tour de force of chemical biology, Breslow started with DMSO as a lead for cell 
differentiation and eventually progressed to a more active series of hydroxamic acids 
culminating in suberoylanilide hydroxamic acid (SAHA).47 Later acquired by Merck, 
SAHA now known as vorinostat (8, Figure 6) became the first HDAC inhibitor to receive 
FDA approval, in 2006 for the treatment of cutaneous T-cell lymphoma. In parallel, the 
depsipeptide natural product romidepsin (3) was also discovered on the basis of 
phenotypic activity before its molecular target was identified. Romidepsin advanced to 
clinical development by Gloucester Pharmaceuticals before receiving FDA approval in 
2009, for cutaneous T-cell lymphoma as well. Another natural depsipeptide, 
spiruchostatin A (OBP-801, 4) is under investigation in Phase 1 clinical trials for the 
treatment of solid tumors.48 Meanwhile, the elucidation of the mechanism of action of 
trichostatin A led to tremendous medicinal chemistry interest in hydroxamic acids as 
HDAC inhibitors and they remain the most popular choice of zinc binding group against 
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this target. Subsequent to vorinostat, six other clinical candidates tefinostat (9),49 
CG200745 (10),50 ricolinostat (11),51 citarinostat (12),52 CUDC-101 (13)53 and 
tinostamustine (14)54 have appeared that feature similar aliphatic hydroxamic acids with 
linear methylene chains. The X-ray structure of the vorinostat-HDAC8 complex (Figure 
7) illustrates the typical bidentate coordination observed with hydroxamic acids within 






































































Figure 6. Clinical candidate HDAC inhibitors with aliphatic hydroxamic acids.
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Figure 7. The binding interactions in the vorinostat-HDAC8 X-ray structure. The zinc 
cation is displayed as a centroid with the coordinating Asp and His residues in pink. The 
His and Tyr residues involved in water activation and substrate binding respectively are 
indicated in blue. Reprinted with permission from ref. 55.
A second family of HDAC inhibitors, inspired by trichostatin A, contains a more rigid 
alkenyl hydroxamic acid. In 2014, belinostat (15, Figure 8) originating from Prolifix and 
now marketed by Onxeo/Spectrum, became the third HDAC inhibitor to be approved for 
T-cell lymphoma after vorinostat and romidepsin.56 A year later, Novartis’s panobinostat 
(16) was approved for the treatment of relapsed or refractory multiple myeloma by both 
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the FDA and the EMA.57 Two other alkenyl hydroxamic acids resminostat (17)58 and 
pracinostat (18)59 are in clinical trials. A newer series of compounds contains an even 
more rigid phenylhydroxamic acid: givinostat (19, Figure 9),60 abexinostat (20),61 AR-42 
(21)62 and bisthianostat (22).63 A more polar pyrimidinyl heteroaromatic hydroxamic acid 

































Figure 8. Clinical candidate HDAC inhibitors with alkenyl hydroxamic acids.
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Figure 9. Clinical candidate HDAC inhibitors with aromatic hydroxamic acids.
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Pharmacodynamic data against individual HDAC isoforms is available for the approved 
drugs and the majority of clinical candidates (Table 3). Romidepsin has the typical 
profile of natural product HDAC inhibitors, with a high activity against the nuclear 
isoforms HDAC1-3.67 There is selectivity, as the natural product is sparing against 
HDAC8 and HDAC6 although the non-acetyllysine hydrolyzing HDAC10 and HDAC11 
are also strongly inhibited. Compared to romidepsin, the forerunner of the hydroxamic 
acids, vorinostat, has a saturated aliphatic linker and a phenyl cap. With its relatively 
simple and unconstrained structure, vorinostat would not be predicted to be selective 
(nor was it intended to be, since the subtleties of isoform function were unknown at the 
time), and in biochemical enzyme assays it inhibits both the nuclear and cytoplasmic 
HDACs indiscriminately at submicromolar levels. Although the later hydroxamic acids 
show an extensive diversity in the architecture of their linker and cap regions, they 
share a common pharmacological profile insofar that all potently inhibit HDAC1-3 just 
like vorinostat or romidepsin.
HDAC isoform IC50, nM
Cpd. 1 2 3 8 4 5 7 9 6 10 11
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60 42 36 173 20 36 129 49 29 60 31
ricolinostat 
(11)
58 48 51 100 >1000 >1000 >1000 >1000 5 - >1000
citarinostat 
(12)
35 45 46 137 >1000 >1000 >1000 >1000 3 - -
belinostat 
(15)a
26 22 19 22 15 25 51 24 10 59 27
panobinostat 
(16)a
3 2 2 22 1 1 2 1 1 31 4
pracinostat 
(18)a
28 27 19 48 16 21 104 24 247 23 24
givinostat (19) 133 293 136 837 >1000 532 524 512 312 331 287
abexinostat 
(20)
21 63 148 370 60 48 350 168 12 52 14
bisthianostat 
(22)
4 13 6 17 >1000 >1000 >1000 >1000 2 2 78
quisinostat 
(23)
0.1 0.3 5 4 0.6 4 119 32 77 0.5 0.4
fimepinostat 
(25)
2 5 2 191 409 674 426 554 27 3 5
Table 3. IC50 values of clinical candidate and approved thiol and hydroxamic acid HDAC 
inhibitors. aFor these compounds, Ki values are given, from a side-by-side comparison in 
ref. 59. Data for other compounds compiled from refs. 51, 52, 60, 61, 63, 64 and 66.
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Besides the hydroxamic acids, ortho-aminoanilides (or benzamides) are a second class 
of synthetic HDAC inhibitors that have yielded clinical candidates. X-ray crystallography 
of enzyme-inhibitor complexes shows bidentate coordination of the carbonyl oxygen 
and aniline nitrogen with the active site zinc cation. Nevertheless, ortho-aminoanilides 
would be expected to be weaker metal binders than hydroxamic acids, and this is 
reflected in their typical micromolar IC50 values in standard assay conditions compared 
to the nanomolar potency of the latter. However, the ortho-aminoanilides exhibit unusual 
kinetics, being tight-binding inhibitors with slow-on/slow-off rates that benefit from pre-
incubation and equilibration compared to the fast-on/fast-off behavior observed with 
hydroxamic acids. For example, with pre-incubation, an ortho-aminoanilide had Ki 
values of 148 and 5 nM respectively against HDAC1 and HDAC3, compared to 5 and 8 
nM respectively for vorinostat (whose activity was unchanged upon pre-incubation).68 
Pfizer’s tacedinaline (26, Figure 10)69 was an early clinical candidate with a simpler cap 
compared to entinostat (27)70 and mocetinostat (28).71 Tucidinostat (29) from Shenzen 
Chipscreen Biosciences received approval from the CFDA in 2015 for the treatment of 
peripheral T-cell lymphoma and marks the first example of a ‘Made in China’ drug 
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where the entire drug discovery process was carried out there.72 Domatinostat (30)73 
and CXD101 (31)74 are additional ortho-aminoanilides in clinical trials.
The available literature data on ortho-aminoanilides (Table 4) indicates they are similar 
as a class, inhibiting HDAC1-3 while poorly active against HDAC6 and HDAC8. The 
larger dimensions of the ortho-aminoanilide compared to a thiol or hydroxamic acid zinc 
binding group can be accommodated by the lateral cavity present in HDAC1-3 but 
absent in HDAC6. Although HDAC8 contains the lateral cavity, the substitution of a 
tryptophan residue for a leucine present in HDAC1-3 leads to a shallower channel that 
does not bind to the ortho-aminoanilide. To some extent, the ortho-aminoanilides are 
similar in their activity profile to romidepsin and related depsipeptide natural products in 
that they predominantly inhibit HDAC1-3.
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Figure 10. Clinical candidate ortho-aminoanilide HDAC inhibitors.
HDAC isoform IC50, M
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- - - - - - - -
Table 4. IC50 values of clinical candidate and approved ortho-aminoanilide HDAC 
inhibitors compiled from refs. 69-74. Note that values are in M, unlike the nM in Table 
3 and assay conditions may not have involved enzyme pre-incubation.
In addition to the compounds discussed above, there are HDAC inhibitors in Phase 1 
clinical trials with undisclosed structures: CKD-504 and CKD-506 (Chong Kung Dan 
Pharmaceutical Corp.), CS3003 (CStone Pharmaceuticals), HG146 (HitGen), KA2507 
(Karus Therapeutics) and OKI-179 (OnKure). The majority are reported to be HDAC6 
selective inhibitors, while OKI-179 is a synthetic analogue of largazole (5).
HDAC inhibitors as cytotoxic agents
After the DNMTs, HDACs were the next epigenetic target to receive scrutiny for drug 
discovery and this rapidly accelerated with the early discovery of compounds that 
displayed potent antiproliferative activity in human cancer cell lines that was 
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recapitulated in tumor xenograft animal models. At the same time, the simplicity and 
flexibility of the HDAC pharmacophore provided medicinal chemists with the freedom to 
operate and design and optimize independent lead series. Since the first-in-human 
experiments with vorinostat in 2000, HDAC inhibitors have been investigated in nearly a 
thousand clinical trials, primarily in oncology but numerous other indications as well. It is 
fair to say the accumulated clinical experience from the last two decades is 
disappointing as it did not fulfill the promise of the earlier data from in vitro and in vivo 
models. Efficacy with an acceptable margin of safety and tolerability has mainly been 
observed in certain hematological cancers.75,76 To date, we have four approvals for T-
cell lymphoma,  one for multiple myeloma and one for combination therapy against 
breast cancer, and the HDAC inhibitors are not first-line therapy against any of these 
indications.
What HDAC inhibitors actually do in cells is an extremely complicated question. 
Microarray experiments indicate that <10% of the genome undergoes significantly 
altered expression upon treatment with a HDAC inhibitor.77 In a cancer cell, these 
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perturbations appear to disrupt their metastable state and drive the cell towards non-
proliferative fates involving a combination of differentiation, immunomodulation, 
chromatin instability, reduced DNA damage repair, reactive oxygen species production, 
cell cycle arrest, apoptosis, autophagy, and the reduction of angiogenesis and cell 
migration.78 These effects are most strongly felt in hematological cancers, perhaps due 
to the fact that the tumor is derived in a complex process of hematopoiesis from stem 
cells. Epigenetic programming plays a heavy role in this transformation, and the blood 
cell lineages appear to be more plastic and susceptible to reprogramming compared to 
more terminally differentiated cancer types. The particular success in the treatment of T-
cell lymphoma is strongly linked to immunomodulation, as HDAC inhibitors cause a 
reduction in the ‘cytokine storm’ characteristic of this disorder.79 Meanwhile, it has 
proven challenging to find a therapeutic window that allows the higher dosing needed 
against more aggressive cancers without compromising patient tolerability.80 Resistance 
to HDAC inhibitors is a further issue,81 mainly arising via compensating changes in 
HAT/HDAC expression levels, the induction of p21 (CIP1/WAF1) and thioredoxin, and 
drug efflux by ABC transporters.
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The first clinical candidates vorinostat and romidepsin have limited oral bioavailability 
and their trials required intravenous administration. Romidepsin, with its complex 
structure, was considered intractable for analogue generation although this would 
eventually change through the design of efficient total synthesis routes by academic 
groups.82 While vorinostat is a much simpler molecule and an oral formulation was later 
developed, it suffers from extensive metabolism through hydroxamic acid 
glucuronidation and oxidative cleavage of the aliphatic methylene chain. For fast 
followers, the main challenge was to improve target affinity and the pharmacokinetic 
liabilities and both aspects were successfully addressed in second generation HDAC 
inhibitors. However, the primary focus was cancer, in which the cytotoxic activity is 
largely driven by the inhibition of HDAC1-3. Thus, medicinal chemistry lead optimization 
consciously or subconsciously selected for compounds with high activity against these 
nuclear isoforms. In the clinic, both the older and the newer compounds exhibit a similar 
pattern of dose limiting toxicities and adverse events dominated by fatigue, diarrhea, 
bone marrow toxicity, thrombocytopenia and in some cases cardiac abnormalities. 
Since these are observed regardless of the nature of the inhibitor, they are likely to be 
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on-target effects due to systemic HDAC inhibition rather than compound specific 
idiosyncrasies. The pleiotropic nature of the cellular response to HDAC inhibition is 
indicative of a global disruption of gene expression, which leads to the following 
conclusions:
1. The clinical effects are driven by HDAC1, HDAC2 and HDAC3 inhibition
The inhibition of these isoforms increases the acetylation of histones and other nuclear 
proteins, leading to gene activation through increased accessibility of DNA by RNA pol 
II and the promotion of protein-protein interactions between bromodomain containing 
proteins and acetyllysine residues. Our current portfolio of clinical candidates (Tables 3 
and 4) is unanimously identical in its high activity against HDAC1-3 and we believe this 
is the reason why compounds are not particularly differentiated from one another in their 
biological effects.
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2. The inhibition of isoforms in addition to HDAC1-3 by current candidates is likely to be 
undesirable
The clinical compounds primarily vary in their selectivity between the nuclear isoforms 
HDAC1-3 and the cytoplasmic HDAC6. Some inhibit both the nuclear and cytoplasmic 
enzymes strongly (e.g. vorinostat and fast followers) while others are either selective for 
HDAC1-3 (e.g. romidepsin, ortho-aminoanilides) or HDAC6 (e.g. ricolinostat). However, 
these differences have not translated into major shifts in therapeutic application or 
dramatic clinical benefit for one compound over another. Meanwhile, a lack of activity 
observed in enzyme assays against HDAC4, HDAC5, HDAC7 and HDAC9 is a 
misleading measure of selectivity, as a compound may still be capable of binding to the 
active sites and thereby abrogate their non-enzymatic role in protein scaffolding. As for 
HDAC8, HDAC10 and HDAC11, the traditional assays indicate differing levels of 
inhibition that may again be of questionable relevance given their preference for non-
acetyllysine substrates. Although there are fine distinctions in biochemical in vitro 
selectivity between the clinical inhibitors in Tables 3 and 4, this may conceal a broader 
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in vivo spectrum of activity against the majority of isoforms. While the inhibition of 
isoforms other than HDAC1-3 may be beneficial, in nonselective compounds any 
advantage that accrues is likely to be swamped out by the side effects arising from 
HDAC1-3 inhibition. The history of medicinal chemistry suggests that improved target 
selectivity usually leads to a superior safety profile, and this is likely to hold true for 
HDACs as well.
3. The clinical compounds are cytotoxic agents
Although HDAC inhibitors are a modern chapter in drug discovery, their phenotypic 
effects are widespread and not restricted to a particular cellular pathway or 
compartment. Their activity profile as drugs, at least in its present manifestation, is 
reminiscent of classical cytotoxic agents rather than a targeted therapy. In their account 
of the discovery of vorinostat (SAHA),47 Breslow and Marks made these prescient 
comments: ‘Even if some increase or decrease in transcription of particular genes is 
helpful in the anticancer effects of SAHA, as has been proven to be the case, a 
continuing long-term modulation induced by a drug that is slowly released from the 
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receptor pocket—and indeed might bind reasonably strongly to other sites—could 
cause undesirable effects. SAHA has hit the happy medium. It is potent enough to be 
useful and tolerated in patients. If the dosing is intermittent, such as not to maintain a 
continuous ‘therapeutic’ level of SAHA, it can be released from the binding site 
periodically so as to allow the deacetylation activities in cells. This is a general 
consideration, which could well be true of many other medicinal compounds. Thus, it is 
probably a mistake for medicinal chemists to set out first to find the most potent 
compound they can achieve in a series and then to look at any question of toxicity, as is 
often done. As with SAHA, in other series there will be examples in which the medium 
potency compound has enough efficacy to be a useful drug but not so much as to cause 
unacceptable side effects.’
Clinical performance of HDAC inhibitors
Monotherapy
Aside from the approvals in hematological cancers, HDAC inhibitors are under 
exploration in single agent Phase 2/3 clinical trials for other oncology applications as 
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well as non-cancer indications (Table 5). Among these examples, tefinostat is designed 
to have selective toxicity in liver cancer. Hepatocytes express carboxylesterase-1 that 
hydrolyzes the tefinostat ester to a pharmacologically active carboxylic acid which is 
retained due to its ionized nature, whereas in other cells efflux of the neutral drug limits 
exposure. Panobinostat, aside from its approval in multiple myeloma, is under 
investigation as an immunomodulator for graft-versus-host diseases following allogeneic 
hematopoietic stem cell transplantation.83 Outside oncology, vorinostat is in early 
studies for the treatment of epilepsy84 and Cushing’s disease.85 Meanwhile, Italfarmaco 
is pursuing the development of givinostat for Duchenne and Becker muscular 
dystrophy,86 while Regenacy is targeting ricolinostat for diabetic neuropathic pain.87 
Early indications from multiple myeloma clinical trials are encouraging regarding the 
tolerability of ricolinostat, 10-fold selective for HDAC6 over HDAC1-3, compared to 
inhibitors with lower selectivity.88 
Cpd. Organization Indication Status
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vorinostat Merck cutaneous T-cell lymphoma
epilepsy
Cushing’s disease






tefinostat GlaxoSmithKline hepatocellular carcinoma Phase 1/2, 
#02759601
ricolinostat Regenacy diabetic neuropathic pain Phase 2, #03176472
belinostat Onxeo, Spectrum peripheral T-cell lymphoma FDA approved
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abexinostat Xynomics follicular lymphoma




entinostat Syndax breast cancer, + 
exemestane
renal carcinoma, + IL-2
Phase 3, #02115282 
and #03538171
Phase 2, #03501381
tucidinostat Chipscreen peripheral T-cell lymphoma
B-cell lymphoma
breast cancer, + 
exemestane
soft-tissue sarcoma, + 
toripalimab
CFDA approved
Phase 3, #04231448 
NMPA approved
Phase 2, #04025931
domatinostat 4SC GI cancers, +avelumab Phase 2, #03812796
Table 5. Drug approvals and examples of Phase 2/3 trials conducted with HDAC 
inhibitors. For combination trials, the other drugs involved are indicated with ‘+’. The 
clinical trial is identified by the ClinicalTrials.gov NCT number.
Combination therapy
Page 53 of 111
ACS Paragon Plus Environment






























































The development of resistance is a major obstacle to cancer chemotherapy, and one of 
the contributing factors is the stem cell-like tumor phenotype that fosters epigenetic 
reprogramming in response to the drug. This suggests that combination with a HDAC 
inhibitor could be valuable in sensitizing cancer cells to the treatment, and many clinical 
trials have investigated this hypothesis.89,90 Combination therapy of HDAC inhibitors 
with cytotoxic agents has not shown significant promise, and this further supports our 
conclusion that nonselective HDAC inhibitors themselves behave as cytotoxic agents. 
Meanwhile, the approval of panobinostat for multiple myeloma has led to multiple trials 
with first-line therapies against this indication such as bortezomib and lenalidomide.91 
Numerous studies have focused on the potential synergy between kinase and HDAC 
inhibitors, and a Phase 3 trial is investigating the combination of abexinostat and 
pazopanib.92
Promising results were observed in the treatment of postmenopausal breast cancer 
using the combination of the aromatase inhibitor exemestane and the ortho-
aminoanilide HDAC inhibitor entinostat.93 A larger Phase 3 trial in China with a similar 
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combination of exemestane and tucidinostat reported positive results that led to the 
2019 NMPA approval of this combination for the treatment of breast cancer.94 This 
landmark event represents the first approval of a HDAC inhibitor for an indication 
outside hematological cancers.
Since both HDACs and DNMTs are transcriptional repressors, combined epigenetic 
therapy against these two targets is an attractive proposition. Pracinostat is in late stage 
trials in combination with the DNMT inhibitor azacitidine for the treatment of 
myelodysplastic syndrome and newly diagnosed acute myeloid leukemia.95,96 At an 
earlier stage, biologic antibodies, including immunotherapy agents,97 are being explored 
in combination trials with various HDAC inhibitors. Among the non-oncologic indications, 
the ability of HDAC inhibitors to reactivate latent reservoirs of the HIV virus to undergo 
replication appears to be the most promising for combination therapy. The potency of 
romidepsin in inhibiting the nuclear HDAC1-3 isoforms suggests it is a good candidate 
for viral transcriptional activation, and Phase 2 trials with the neutralizing antibody 
3BNC117 are underway.98
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An interesting approach to leveraging HDAC inhibitors is to take advantage of their 
simple three-point binding model. Since the cap region is not involved in critical contacts 
with the active site, it is possible to introduce an independent second pharmacophore 
here to give dual mechanism of action agents that achieve the equivalent of 
combination therapy within a single entity.99,100 The US company Curis has pioneered 
this strategy, and their first clinical candidate CUDC-101 is a hybrid of vorinostat and 
erlotinib with a nanomolar activity profile against both HDACs and receptor tyrosine 
kinases.101 A second Curis candidate fimepinostat is a hybrid of pyrimidinyl HDAC 
inhibitors and the PI3K inhibitor pictilisib, with nanomolar IC50 values against all four 
PI3K isoforms in addition to its HDAC inhibition. Fimepinostat has received FDA Fast 
Track status for the treatment of relapsed or refractory diffuse large B-cell lymphoma.102 
It was shown to be similarly potent as romidepsin in the reversal of HIV-1 latency, 
without a negative effect on T cell proliferation.103 Mundipharma’s tinostamustine is a 
more recent dual mechanism of action agent related to the DNA alkylating agent 
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bendamustine, and combines this activity with HDAC inhibition. Serendipitously, the 
HDAC inhibitor domatinostat was recently found to have a second target as it potently 
inhibits tubulin polymerization.104 Larger late stage trials are needed before the efficacy 
and tolerability of these four multitargeting drugs can be evaluated in a clinical setting.
Atypical HDAC inhibitors
Not all HDAC inhibitors fully adhere to the classical zinc binding group-linker-cap model 
and some outliers illustrate the possibilities for such non-conformist compounds. 
Intriguingly, Olsen’s romidepsin analogue 32 (Figure 11) has the thiol zinc binding group 
removed.105 While the compound is two orders of magnitude weaker in HDAC inhibition 
than romidepsin, it still possesses a respectable level of activity. Since zinc binding 
groups generally come with associated pharmacokinetic issues, this example suggests 
that it is possible to avoid them altogether if sufficient binding by other means is 
possible. Meanwhile, in the HDAC8 bound X-ray structure of Novartis’s phenylalanine 
derivative 33, the two aromatic rings sit within the hydrophobic substrate channel and 
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the internal cavity (Figure 12), meaning that this inhibitor has no cap.106 The X-ray 
structure shows coordination between the zinc cation and the -aminoamide, a rare 
motif for a zinc binding group. As the internal cavity is absent in HDAC6, 33 is inactive 
against this isoform and moreover shows selectively for HDAC8 over HDAC1 and 
HDAC2. The cyclopentenyl hydroxamic acid 34 is an even more minimal ‘capless’ 
HDAC inhibitor with some selectivity for HDAC6.107
Two other unusual HDAC inhibitors are 35 and 36. The benzoylhydrazide 35 is a typical 
example of this class with reported selectivity for the nuclear isoforms HDAC1-3.108 
Although X-ray crystallographic evidence of the binding mode is unavailable, docking 
studies suggest zinc coordination is not involved and the compound has unusual fast-
on/slow-off kinetics. On the other hand, the vorinostat analogue 36 highlights that the 
linker is not just a space filling moiety. By switching from the suberoyl linker to its 
perfluorinated variant, the activity of the approved drug is virtually lost against human 
HDACs. However, 36 gains in potency against two bacterial HDAC-like enzymes 
PA3774 and PA0321 from the pathogen Pseudomonas aeruginosa.109
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Figure 11. Some examples of unusual HDAC inhibitors. In this and subsequent figures, 
IC50 values (or in some instances Ki) against individual isoforms are given, with values 
below 1 M highlighted in red.
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Figure 12. X-ray structure of the 33-HDAC8 complex showing active site interactions. 
Reprinted with permission from ref. 106.
The heterocycle 37, despite its compact nature and apparent lack of a linker or zinc 
binding group, was reported to selectively inhibit HDAC8. Further investigation revealed 
that 37 is an electrophilic thiol-reactive species that leads to covalent modification of the 
Cys28, Cys153, Cys244, Cys314 and Cys352 residues within HDAC8.110 Both mixed 
disulfide and thiocyanate adducts were identified, and enzyme inhibition was predicted 
to be predominantly due to reaction with the Cys153 residue within the substrate 
binding channel of this isoform. Perhaps the romidepsin analogue 32 has a similar 
mechanism of action involving allosteric modification of Cys residues by conjugate 
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addition to the dehydroalanine residue, as this would explain why a similar largazole 
analogue lacking the unsaturated alkene was devoid of activity.
Naturally, allosteric modulators need not adhere to the standard model for HDAC active 
site binding. However, there are few examples of small molecules reported to bind with 
high affinity to HDACs outside the active site. Tasquinimod (38) is an antagonist of the 
calcium-binding protein S100A9 in Phase 3 clinical trials for castration-resistant prostate 
cancer. It was also shown to bind HDAC4 with a Kd of 10-30 nM, and homology 
modeling suggests allosteric binding that locks HDAC4 in an inactive conformation that 
is unable to interact with HDAC3.111 In endothelial cells, the administration of 
tasquinimod induced the same phenotype of reduced vascular inflammation as HDAC4 
silencing, suggesting that the interaction between HDAC4 and tasquinimod does have a 
functional consequence.112
Isoform selectivity
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At the preclinical stage, the most exciting development in HDAC inhibitor discovery is 
the identification of compounds with an enhanced isoform selectivity profile compared to 
those in clinical development. At the same time, it is worth asking what selectivity 
actually means. The enzymatic activity of HDAC1, HDAC2, HDAC3 and HDAC6 can be 
reliably tracked with acetyllysine containing peptides and provides meaningful data on 
inhibitor selectivity between these isoforms, keeping in mind that in vivo kinetics while 
bound to other proteins and acting upon protein substrates will be different. For all other 
HDAC isoforms, in vitro selectivity as measured by commercial assays is of varying 
physiological relevance and needs to be backed up by independent demonstration of 
cellular target engagement through orthogonal detection methods. Despite these 
caveats, highly selective compounds are now available that are valuable tools for 
understanding the optimum specificity for cancer and neurodegenerative disorders, two 
of the most important targets for HDAC inhibitors.113,114 In addition, selective inhibitors 
are likely to be crucial for extending HDAC inhibition therapy to chronic diseases that 
require wider safety profiles such as inflammation,115 T-cell regulation,116 obesity,117 
fibrosis,118 and alcohol use disorder.119
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There are several patterns of isoform selectivity that appear particularly promising. 
Firstly, targeting transcriptional regulation would benefit from the selective inhibition of 
the nuclear enzymes HDAC1, HDAC2 and HDAC3 (or a subset of these three) with 
minimal activity against other isoforms. Conversely, selective cytoplasmic HDAC6 
inhibition will have its own therapeutic applications if unaccompanied by interference 
with nuclear isoforms. Next, there is the opportunity to focus on the turnover of non-
acetyllysine PTMs or polyamine acetylation through the selective inhibition of HDAC8, 
HDAC11 or HDAC10. Finally, the active site occupancy of HDAC4, HDAC5, HDAC7 or 
HDAC9 (without necessarily affecting catalysis) might be sufficient for pharmacological 
activity and eliminate their ability to bind acetyllysine containing proteins. Moreover, 
more complex composite patterns of selectivity can be envisioned that combine one or 
more of the above options without reaching the unwanted inhibition of all eleven 
enzymes to a substantial degree.
HDAC1 and HDAC2
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Selective inhibitors of these nuclear isoforms would be particularly useful against 
indications such as cancer and viral replication in which the deacetylation of histone and 
transcriptional regulators plays a vital role. Although the clinical compounds adequately 
inhibit HDAC1 and HDAC2, they are also active against some or all of the other 
isoforms at physiologically relevant concentrations (Tables 3 and 4) and a cleaner 
profile could be advantageous. Merck discovered that the addition of a 5-phenyl or 5-
thienyl substituent to ortho-aminoanilide HDAC inhibitors, as exemplified by 39 and 40 
(Figure 13),120,121 or by Acetylon’s ACY-957 (41), conferred high HDAC1/HDAC2 
selectivity. The aryl group of the biphenyl moiety occupies the internal cavity, and in 
these two isoforms there is a Ser107 residue while HDAC3 contains a bulkier Tyr 
residue that limits access. Compound 39 outperformed nonselective HDAC inhibitors in 
vitro and in vivo against B-cell acute lymphoblastic leukemia, but not other B-cell–
derived malignancies, suggesting the selective inhibition of HDAC1/HDAC2 is sufficient 
for this condition.122 As a single agent and in combination with the DNMT inhibitor 
azacitidine, 41 had promising results against acute myeloid leukemia, including activity 
against primary patient derived cells and in vivo xenograft models.123 The PROTAC 
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approach of recruiting an E3 ubiquitin ligase to foster degradation of a protein of interest 
has recently been applied to epigenetic targets.124 The ortho-aminoanilide 42 
incorporates a ligand for the von Hippel-Lindau E3 ligase.125 Treatment of HCT116 cells 
with 10 M of 42 for 24 hours led to nearly complete degradation of HDAC1 and 
HDAC2.
HDAC2 is implicated in the negative regulation of memory formation and synaptic 
plasticity in the brain, with long-term potentiation impaired in HDAC2 overexpressing 
mice.126 Treatment with vorinostat ameliorated contextual fear conditioning but had no 
effect in HDAC2-deficient mice, suggesting non-redundancy between HDAC2 and 
HDAC1. While the high sequence homology between these two isoforms is an obstacle 
to the development of inhibitors that discriminate between the two, there are examples 
of ortho-aminoanilides that achieve a level of kinetic selectivity. Although the Broad 
Institute’s BRD4884 (43) inhibits HDAC1 more strongly, it has a residence time half-life 
of 20 minutes with HDAC1 compared to 143 minutes with HDAC2.127 In the BRD4884-
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HDAC2 X-ray structure (Figure 14), there is a bridging water molecule between the 





































































Figure 13. Examples of biaryl ortho-aminoanilide selective HDAC1/HDAC2 inhibitors.
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Figure 14. The X-ray structure of 43-HDAC2 is typical of ortho-aminoanilides. Bidentate 
coordination is observed with the zinc cation, while the addition of a 5-aryl substituent 
enables occupancy of the lateral internal 14Å cavity. Reprinted with permission from ref. 
127.
HDAC3
HDAC3 exists in multiprotein complexes that contain NCoR/SMRT which are distinct 
from the repressor complexes occupied by HDAC1/HDAC2. Furthermore, the selective 
inhibition of HDAC3 offers the ability to indirectly modulate the tissue-specific 
HDAC4/HDAC5/HDAC7/HDAC9, since they recruit acetyllysine containing substrates 
for hydrolysis by HDAC3. The design of selective HDAC3 inhibitors has recently been 
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comprehensively reviewed.128 The 4-fluoro derivative (44, Figure 15) of the clinical 
candidate tacedinaline has a markedly HDAC3 selective profile compared to the latter 
attributed to both steric and electronic effects.129 The more extended cap in RGFP996 
(45) from Repligen results in even higher selectivity for HDAC3 over other isoforms. 
More recently, the amide bearing HDAC3 selective inhibitor 46 has been reported,130 
which will be useful in teasing out any compound class specific properties of the ortho-
aminoanilides 44 and 45.
The availability of HDAC3 selective probes has proven to be illuminating in a number of 
in vivo disease models. In CNS applications, 45 has promoted the extinction of drug-
seeking behavior,131 induced memory enhancement,132 reduced cognitive decline in 
Huntington’s and Alzheimer’s disease,133,134 and was protective in a stroke model.135 
Furthermore, 45 activated brown and beige fat suggesting potential cardiovascular 
applications arising through the involvement of HDAC3 with the transcriptional 
coactivator PRDM16.136 Meanwhile, 44 was shown to reactivate HIV-1 replication from 
resting CD4+ T cells isolated from antiretroviral-treated, aviremic HIV+ patients,137 and 
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Figure 15. Examples of selective HDAC3 inhibitors.
HDAC6
The inhibition of HDAC1-3 is critical for achieving a truly epigenetic effect involving 
transcriptional regulation in the nucleus. On the other hand, orthogonal inhibition of the 
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major cytoplasmic isoform HDAC6 is potentially valuable against a host of human 
diseases. HDAC6 knockout mice are viable and fertile, and although abnormalities were 
reported in dopaminergic signaling,139 this is in stark contrast with the lethality or clearly 
defective phenotypes observed with other isoforms. This suggests that a highly 
selective HDAC6 inhibitor would be well tolerated and avoids the on-target side effects 
of more promiscuous compounds. The substrate channel in HDAC6’s second catalytic 
domain (CD2) is wider and shallower compared to HDAC1-3, favoring compounds with 
shorter linkers and larger, extended caps. However, because of similarities in the active 
sites between HDAC6 and HDAC8, discriminating between these two isoforms is more 
challenging. Kozikowski has pioneered the development of HDAC6-selective 
arylhydroxamic acid inhibitors such as tubastatin A (47, Figure 16) which is widely 
employed as a tool compound.140  Kozikowski’s SW-100 (48) and Liou’s MPT0G211 
(49) are examples of more recent brain-penetrant inhibitors with a superior 
HDAC6/HDAC8 selectivity profile compared to tubastatin A.141,142 Instead of a phenyl 
linker, Acetylon’s ACY-1083 (50) contains a pyrimidinyl ring and is reported to be > 250-
fold selective for HDAC6 over other isoforms.143
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A PROTAC example with a nonselective hydroxamic acid HDAC iunhibitor linked to a 
cereblon ligand nevertheless led to the selective degradation of HDAC6.144 
Subsequently, the group reported 51 in which the HDAC6 selective scaffold of 
nexturastat A was affixed to the cereblon ligand pomalidomide.145 In MM1S cells, 51 
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Figure 16. Examples of selective HDAC6 inhibitors. See also the HDAC10 discussion 
on tubastatin (47) and analogues.
X-ray crystallographic studies with HDAC6 selective arylhydroxamic acids indicate 
mono-coordination within the shallower active site compared to the more common 
bidentate zinc coordination observed against other isoforms.146  Meanwhile, the aryl 
group engages in  interactions with the substrate channel while the cap extends into 
the solvent exposed enzyme rim, as illustrated by the binding of 50 to HDAC6 (Figure 
17). Recent studies (see below), suggest that tubastatin and related compounds with a 
basic amine in the linker or cap region are also capable of inhibiting the 
acetylspermidine hydrolysis activity of HDAC10. 
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Figure 17. a) Simulated annealing omit map of the 50-HDAC6 (catalytic domain 2) 
binding. The hydroxamic acid engages in mono-coordinate interactions with the zinc 
cation while the carbonyl group hydrogen bonds the active site water involved in amide 
hydrolysis. The linker makes an additional hydrogen bond with Ser531. b) Cut-away 
view of the active site surface highlighting the zinc coordination polyhedron and the 
aromatic interactions between the inhibitor and the substrate binding channel. Reprinted 
with permission from ref. 146.
The inhibition of HDAC6 has been extensively studied in cell-based and in vivo disease 
models, although some examples involved compounds with lower selectivity profiles 
than 47-51 and phenotypic effects may be due to residual effects against other HDAC 
isoforms. Robust data has been obtained in animal models for cancer and 
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neurodegenerative disorders, with early stage clinical trials ongoing for the treatment of 
hematological malignancies, solid tumors and Huntington’s disease, as well as 
Regenacy’s planned Phase 2 trial with ricolinostat for diabetic neuropathic pain.147,148 In 
addition, earlier preclinical studies are promising against a number of other 
indications.149
HDAC8
The challenge with HDAC8 inhibition is to avoid hitting the other nuclear isoforms 
HDAC1-3 as well as the cytoplasmic HDAC6.150 With regards to the latter, ortho- or 
meta-substituted aromatic linkers are helpful, compared to the para-substitution typical 
in HDAC6 selective inhibitors. Pharmacyclic’s PCI-34051 (52, Figure 18) was the first to 
exhibit high selectivity for HDAC8 and is the most widely used tool compound for this 
isoform.151 Newer examples include Huang’s cinnamoyl terphenylhydroxamic acid WK2-
16 (53) and Beeler’s phenylalanine derived hydroxamic acid 54.152,153 In animal models, 
selective HDAC8 inhibitors have shown promise in neuroblastoma154 as well as different 
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inflammatory settings such as hypertensive inflammation,155 neuroinflammation156 and 
airway inflammation.157 Recently, 52 was shown to resensitize melanoma tumor 















































Figure 18. Examples of selective HDAC8 inhibitors.
HDAC11
The first selective HDAC11 inhibitor FT895 (55, Figure 19) was recently reported by 
FORMA, and modeling suggests that the pyrazine ring extends into the internal cavity 
adjacent to the zinc cation.159 While fluorescent acetyllysine peptide substrates were 
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used in FORMA’s enzymatic assays, Lin employed a potentially more relevant 
myristoyllysine peptide with HPLC monitoring to discover acylhydrazide inhibitor 56.160 
In this assay, 55 and 56 were of similar potency in inhibiting demyristoylation. 
Presumably, 56 binds to HDAC11 with the alkyl chain occupying the internal cavity. 
With the availability of such probes, in vivo investigations will become possible to 






















Figure 19. Examples of selective HDAC11 inhibitors.
HDAC10
The profiling of approved and clinical candidate HDAC inhibitors indicates that many 
strongly inhibit HDAC10 in assay kits employing trifluoroacetyllysine substrates. 
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Although we now know that HDAC10 is a small molecule polyamine deacetylase, the 
assay results indicate that many HDAC inhibitors are capable of entering and occupying 
the substrate channel. Recently, instead of the conventional monitoring of product 
formation, Miller employed a FRET ligand displacement assay. In this assay, the 
HDAC6 selective inhibitor tubastatin A (47) actually bound more strongly to HDAC10 
than HDAC6.161 Since tubastatin A was much more effective than other HDAC inhibitors 
tested, it is likely that the molecule’s amine forms a favorable electrostatic interaction 
with the glutamate gatekeeper residue unique to HDAC10. From a library of tubastatin A 
analogues, compounds 57 and 58 (Figure 20) were slightly more potent in HDAC10 
binding, perhaps due to a greater rotational flexibility to accommodate interaction with 
the glutamate. Furher improvements will be needed to ensure HDAC6/HDAC10 
selectivity with these tubastatin A based compounds.
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Figure 20. Tubastatin A (47), analogues 57 and 58, and the spermidine hydroxamic acid 
59. Note that IC50 values for 47, 57 and 58 correspond to a FRET displacement assay 
for HDAC10 and enzymatic assays for other isoforms. The value for 59 comes from an 
assay monitoring N-acetylputrescine hydrolysis.
Christianson examined a number of spermidine derivatives as potential inhibitors, using 
an enzymatic assay based on N-acetylputrescine hydrolysis. The hydroxamic acid 59 is 
a submicromolar HDAC10 inhibitor, and the X-ray structure (Figure 21) of 59 omplexed 
to Danio rerio (zebrafish) HDAC10 has provided useful information on the binding 
interactions. The hydroxamic acid engages in bidentate coordination with the zinc 
cation, while the methylene chain features a bifurcated hydrogen bond between the 
secondary amine NH proton and the gatekeeper glutamate residue.162
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Figure 21.  Polder omit map of 59 bound to the active site of HDAC10. The hydroxamic 
acid is coordinated as a bidentate ligand to the zinc cation, while the NH proton 
engages in hydrogen bonding with the Glu274 gatekeeper residue. Reprinted from ref. 
162.
HDAC4/HDAC5/HDAC7/HDAC9
Since these isoforms have low catalytic activity, assays have employed mutant 
enzymes or reactive trifluoroacetyllysine substrates. While the physiological relevance 
of such data is questionable, it does give an idea of active site occupancy. The highly 
selective inhibitor TMP269 (60, Figure 21) was reported by Tempero and contains an 
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unusual oxadiazole zinc binding group.163 The X-ray structure of 60 bound to HDAC7 
revealed a U-shaped conformation with interactions between a fluorine and the 
oxadiazole oxygen with the zinc, at relatively long distances of 2.7 Å and 3.0 Å 
respectively compared to the ~2 Å observed with hydroxamic acids. Thus, the binding 
involves weak electrostatic interactions with zinc rather than direct coordination. 
Because these HDACs have an active site tyrosine (Figure 2) replaced by the smaller 
histidine, the more roomy substrate binding channel is able to accommodate the bulky 
trifluoromethyloxadiazole unlike the other isoforms, leading to high selectivity. In mouse 
models, 60 demonstrated protective activity against pulmonary arterial hypertension and 
cerebral ischemia/reperfusion injury.164,165 The structurally related analogue TMP195 
reduced mycobacterial infection in a zebrafish embryo model for tuberculosis.166
The CHDI Foundation reported a more conventional hydroxamic acid inhibitor 61 but 
with an unusual chiral cyclopropane scaffold.167 The first generation compound lacking 
the cyclopropyl fluorine substituent had poorer pharmacokinetic properties due to 
glucuronidation. An X-ray structure of des-fluoro-61 with HDAC4 (Figure 22) indicates 
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bidentate coordination of the hydroxamic acid with the phenyl ring in a lower pocket 
engaged in -stacking interactions. More recently, CHDI have disclosed the aromatic 
hydroxamic acid CHDI-390576 (62) with good plasma, muscle and brain exposure in 




























































Figure 21. Examples of selective HDAC4/HDAC5/HDAC7/HDAC9 inhibitors.
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Figure 22. The binding interactions of des-fluoro-61 (with H instead of F at C1) within 
the HDAC4 active site, showing the occupancy of the selectivity pocket by the phenyl 
ring. Reprinted from ref. 167.
Summary
The timeline from bench to bedside was remarkably speedy for HDACs. The clinical 
trials of a HDAC inhibitor began in 2000, only four years after the first mammalian 
HDAC was characterized. In the last twenty years, over 30 HDAC inhibitors have 
entered clinical development with five regulatory approvals. Nevertheless, these 
medicinal chemistry successes have occurred despite the biological complexity of the 
target. Although there are only eleven human HDACs, this small number carries out a 
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set of at least five cellular functions: nuclear lysine deacetylation (HDAC1/2/3), 
cytoplasmic lysine deacetylation (HDAC6), fatty acid deacylation (HDAC8/11), 
polyamine deacylation (HDAC10) and acetyllysine recognition (HDAC4/5/7/9). We 
believe that selectivity will be the key to unlock the full therapeutic value of HDAC 
inhibitors, and a toolkit of compounds is now available (Table 6) that will fuel future 
discoveries in HDAC biology and drug discovery. 
Isoform Compound class Examples Selectivity 
challenge
HDAC1/2 5-aryl-ortho-aminoanilides 39-43 HDAC1 vs 2
HDAC3 4-fluoro-ortho-aminoanilides 44, 45 HDAC1/2
HDAC6 para-arylhydroxamic acids 47-51 HDAC8/10
HDAC8 ortho/meta-arylhydroxamic acids 52-54 HDAC6
HDAC11 ortho/meta-arylhydroxamic acids 55 HDAC8
HDAC10 basic hydroxamic acids 47, 57-59 HDAC6
HDAC4/5/7/9 oxadiazoles, -branched hydroxamic 
acids
60-62 HDAC4 vs 5 vs 7 vs 
9
Table 6. Summary of the major isoform selective HDAC inhibitors, and the selectivity 
issues faced within each class.
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While the next 30 years are too distant for accurate predictions, we anticipate that major 
advances will already occur within the next decade along many fronts including the 
following:
 Target validation to identify the ideal HDAC inhibitor profile for specific 
therapeutic indications.
 Unconventional approaches to HDAC drug discovery e.g. dual mechanism 
agents, PROTACs, covalent inhibitors, non-active site modulators.
 Personalized medicine and patient stratification strategies, which are rare at the 
present time for HDAC inhibitor therapy.
 Clinical optimization of HDAC dosing regimens, particularly the timing of 
administration for combination therapies.
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ABBREVIATIONS
ABC, ATP-binding cassette; Abl, Abelson murine leukemia viral oncogene homolog; 
ARID, AT-rich interactive domain-containing protein; ATM, ataxia-telangiectasia 
mutated; BAX, BCL2 associated X protein; BRD, bromodomain; CAF, chromatin 
assembly factor; CFDA, China Food and Drug Administration; CIP, cyclin-dependent 
kinase inhibitory protein; CoREST, co-repressor for element-1-silencing transcription 
factor; DC50, half maximal concentration of protein degradation; DNMT, DNA 
methyltransferase; E2F, E2 promoter binding factor; EMA, European Medicines Agency; 
ERR, estrogen-related receptor; FDA, Food and Drug Administration; FOXP, forkhead 
Page 85 of 111
ACS Paragon Plus Environment






























































box P; FRET, fluorescence resonance energy transfer; GR, glucocorticoid receptor; 
GRP, glucose-regulated protein; HAT, histone acetyltransferase; HDAC, histone 
deacetylase; HIF, hypoxia-inducing factor; Hos, Histone deacetylase-A one similar; Hsp, 
heat shock protein; Ku, lupus Ku autoantigen protein; LSD, lysine-specific demethylase; 
MEF, myocyte enhancer factor; MiDAC, mitotic deacetylase complex; MIER, mesoderm 
induction early response; NCoR, nuclear receptor corepressor; NCT, national clinical 
trial; NES, nuclear export sequence; NLS, nuclear localization sequence; NMPA, 
National Medical Products Administration; NuRD, nucleosome remodeling and 
deacetylation; PCAF, P300/CBP-associated factor (KAT2B); PRDM, PR domain 
containing; PROTAC, proteolysis targeting chimera; PTM, post-translational 
modification; SMC, structural maintenance of chromosome; SMRT, silencing mediator 
of retinoic and thyroid receptors; Sin, SWI-independent; STAT, signal transducer and 
activator of transcription; WAF, wild-type activating fragment.
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